Cannabis Stocks Today 16 Nov 2026: Aurora sits at $4.94
Cannabis stocks mostly declined, with 24 of 35 tracked tickers falling. Aurora Cannabis (ACB) dropped 1.00% to $4.94, below takeover offers from Organigram (OGI) and Curaleaf (CURLF). MSOS ETF fell 3.63% to $3.72. Curaleaf reported Q3 revenue of $353M, up 11%. Glass House (GLASF) and Vext Science (VEXTF) saw steep declines.
How this was made

The 30-second read
Why it matters
The only clearly decision-relevant thread is the Aurora acquisition contest (Organigram bid, Curaleaf competitive bid, and the 4 December expiry), while most other quoted moves are not tied to new disclosures.
Market read
Traders can monitor the Aurora bid contest for spread changes, but the rest of the tape is largely descriptive without fresh catalysts.
What to watch
The article emphasizes that several moves lack sourced catalysts; traders may need to check for late filings, deal-spread changes, or liquidity/OTC microstructure before assigning fundamental meaning.
Background
This is a multi-name cannabis market wrap with early-week pre-market weakness and a focus on Aurora’s M&A situation amid competing bids.
Ticker impact
Aurora Cannabis is the article’s named focus, trading at $4.94 down 1.00%, and is tied to Organigram’s $7.80/share buy offer.
Likely range-bound to slightly pressured as traders weigh bid certainty versus deal risk.
The text links ACB to an agreed acquisition price and notes the offer is below the headline value, implying spread compression or widening can drive near-term moves.
Organigram is a named acquirer in the deal, trading at $0.8286 down 0.65% after agreeing to buy Aurora for C$7.80/share.
Likely modest downside or volatility as deal execution risk is repriced.
The article provides the agreed bid price and notes competition clearances for Curaleaf’s rival offer, which can affect perceived odds for OGI’s transaction.
Curaleaf is central to the competitive bid, trading at $7.85 down 2.61%, with CEO commentary that it could raise its Aurora bid with due diligence access.
Likely choppy, with downside risk if traders think Curaleaf will not improve terms before the 4 December expiry.
The article ties Curaleaf’s offer mechanics to Aurora holders and states the rival offer’s competition clearances and expiry date, both of which can drive bid-spread repricing.
The AdvisorShares Pure US Cannabis ETF (MSOS) is explicitly quoted at $3.72, down 3.63%, reflecting broad cannabis weakness in early trading.
Likely continued pressure if pre-market weakness persists and flows remain risk-off.
The article directly reports MSOS’s current move and frames it as part of a broad decline across cannabis-linked tickers.
Village Farms (VFF) is down 4.72% to $2.42, with the article stating no fresh disclosure explains the current level after its 9 November 8-K.
Likely range-bound to slightly lower as traders fade the lack of incremental news.
The article explicitly says no fresh disclosure accounts for the current level, implying the move is not tied to a new fundamental datapoint.
Market effects
Broad cannabis-linked weakness suggests sector-wide risk-off and can widen bid spreads in M&A-linked names.
US pre-market weakness may spill into Canadian-listed cannabis sentiment at the open.
Limited direct global catalyst; mainly reflects North American cannabis tape and deal spread dynamics.
Counterpoint
Some of the biggest losers (especially OTC names) may be liquidity or stale-quote effects rather than new fundamental deterioration.
Key entities
- companyAurora Cannabis
Subject of the article, trading at $4.94 and linked to an agreed acquisition by Organigram.
- companyOrganigram
Acquirer in the Aurora deal, trading at $0.8286 after agreeing to buy Aurora for C$7.80/share.
- companyCuraleaf Holdings
Competitive bidder for Aurora, trading at $7.85, with CEO indicating it could raise its bid with due diligence access.
- fundAdvisorShares Pure US Cannabis ETF
MSOS quoted down 3.63%, signaling broad sector weakness.

